Piper Jaffray Companies cut shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from an overweight rating to a neutral rating in a report issued on Wednesday, MarketBeat.com reports. Piper Jaffray Companies currently has $23.00 price objective on the stock, down from their prior price objective of $24.00. Piper Jaffray Companies also issued estimates for Amphastar Pharmaceuticals’ Q1 2020 earnings at $0.16 EPS, Q2 2020 earnings at $0.23 EPS, Q3 2020 earnings at $0.28 EPS and Q4 2020 earnings at $0.30 EPS.

A number of other analysts have also recently issued reports on the stock. Jefferies Financial Group reiterated a buy rating and issued a $26.00 target price on shares of Amphastar Pharmaceuticals in a research note on Wednesday, November 14th. TheStreet upgraded shares of Amphastar Pharmaceuticals from a c+ rating to a b- rating in a research note on Friday, January 11th. Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, November 13th. Finally, BidaskClub lowered shares of Amphastar Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Monday, February 25th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Amphastar Pharmaceuticals currently has a consensus rating of Buy and an average price target of $23.73.

NASDAQ AMPH opened at $20.23 on Wednesday. The company has a quick ratio of 1.34, a current ratio of 2.02 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of 96.33, a price-to-earnings-growth ratio of 1.81 and a beta of 1.40. Amphastar Pharmaceuticals has a 12-month low of $14.40 and a 12-month high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Tuesday, March 12th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.02. The firm had revenue of $89.69 million during the quarter, compared to analysts’ expectations of $75.46 million. Amphastar Pharmaceuticals had a negative net margin of 1.96% and a positive return on equity of 3.25%. As a group, analysts anticipate that Amphastar Pharmaceuticals will post 0.54 EPS for the current fiscal year.

In other news, EVP Rong Zhou sold 3,200 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $25.00, for a total value of $80,000.00. Following the transaction, the executive vice president now owns 55,230 shares of the company’s stock, valued at $1,380,750. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO William J. Peters sold 1,500 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $25.36, for a total transaction of $38,040.00. Following the completion of the transaction, the chief financial officer now directly owns 77,050 shares in the company, valued at approximately $1,953,988. The disclosure for this sale can be found here. In the last three months, insiders sold 87,222 shares of company stock worth $2,037,797. Insiders own 31.50% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in Amphastar Pharmaceuticals by 4.7% during the third quarter. BlackRock Inc. now owns 5,987,805 shares of the company’s stock worth $115,205,000 after acquiring an additional 267,622 shares during the period. Dimensional Fund Advisors LP increased its position in Amphastar Pharmaceuticals by 7.9% during the third quarter. Dimensional Fund Advisors LP now owns 1,909,883 shares of the company’s stock worth $36,746,000 after acquiring an additional 140,350 shares during the period. Teachers Advisors LLC increased its position in Amphastar Pharmaceuticals by 0.7% during the third quarter. Teachers Advisors LLC now owns 566,984 shares of the company’s stock worth $10,909,000 after acquiring an additional 4,194 shares during the period. Bank of New York Mellon Corp increased its position in Amphastar Pharmaceuticals by 6.7% during the fourth quarter. Bank of New York Mellon Corp now owns 447,128 shares of the company’s stock worth $8,898,000 after acquiring an additional 28,225 shares during the period. Finally, Geode Capital Management LLC increased its position in Amphastar Pharmaceuticals by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 425,301 shares of the company’s stock worth $8,462,000 after acquiring an additional 36,784 shares during the period. 48.22% of the stock is currently owned by institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Read More: What is the NASDAQ Stock Market?

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.